{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:32:18Z","timestamp":1785306738785,"version":"3.55.0"},"reference-count":125,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.chest.2019.05.025","type":"journal-article","created":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T09:53:16Z","timestamp":1561456396000},"page":"604-618","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Direct-Acting Oral Anticoagulants in Critically Ill Patients"],"prefix":"10.1016","volume":"156","author":[{"given":"Parth","family":"Rali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Gangemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee","family":"Moores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Mohrien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Moores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.chest.2019.05.025_bib1","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1378\/chest.11-1396","article-title":"Introduction to drug pharmacokinetics in the critically ill patient","volume":"141","author":"Smith","year":"2012","journal-title":"Chest"},{"issue":"16","key":"10.1016\/j.chest.2019.05.025_bib2","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.chest.2019.05.025_bib3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bcp.12054","article-title":"Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct factor xa inhibitor","volume":"76","author":"Kubitza","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.chest.2019.05.025_bib4","doi-asserted-by":"crossref","unstructured":"Byon W, Garonzik S, Boyd RA, Frost CE. Apixaban: A clinical pharmacokinetic and pharmacodynamic review [published online ahead of print May 14, 2019]. Clin Pharmacokinet. https:\/\/doi.org\/10.1007\/s40262-019-00775-z.","DOI":"10.1007\/s40262-019-00775-z"},{"issue":"4","key":"10.1016\/j.chest.2019.05.025_bib5","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/ejh.12844","article-title":"The efficacy and safety of direct oral anticoagulants vs\u00a0traditional anticoagulants in cirrhosis","volume":"98","author":"Hum","year":"2017","journal-title":"Eur J Haematol"},{"issue":"5","key":"10.1016\/j.chest.2019.05.025_bib6","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/liv.13285","article-title":"Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis","volume":"37","author":"De Gottardi","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.chest.2019.05.025_bib7","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.thromres.2018.08.011","article-title":"Direct oral anticoagulants in patients with liver cirrhosis: a systematic review","volume":"170","author":"Hoolwerf","year":"2018","journal-title":"Thromb Res"},{"issue":"4","key":"10.1016\/j.chest.2019.05.025_bib8","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/hep.27350","article-title":"Decreased in\u00a0vitro anticoagulant potency of rivaroxaban and apixaban in plasma from patients with cirrhosis","volume":"61","author":"Potze","year":"2015","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.chest.2019.05.025_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0088390","article-title":"Differential in\u00a0vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis","volume":"9","author":"Potze","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.chest.2019.05.025_bib10","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40262-013-0034-0","article-title":"Anticoagulant therapy with the oral direct factor xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment","volume":"52","author":"Graff","year":"2013","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"10.1016\/j.chest.2019.05.025_bib11","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1002\/jcph.550","article-title":"An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics","volume":"55","author":"Mendell","year":"2015","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.chest.2019.05.025_bib12","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/CRD.0000000000000227","article-title":"Betrixaban: a novel factor Xa inhibitor for the prevention of venous thromboembolism in acutely ill medical patients","volume":"26","author":"Lee","year":"2018","journal-title":"Cardiol Rev"},{"issue":"4","key":"10.1016\/j.chest.2019.05.025_bib13","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/11318170-000000000-00000","article-title":"Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study","volume":"49","author":"Stangier","year":"2010","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.chest.2019.05.025_bib14","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/jcph.633","article-title":"Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban","volume":"56","author":"Chang","year":"2016","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.chest.2019.05.025_bib15","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1002\/jcph.541","article-title":"Population pharmacokinetics of edoxaban and its main metabolite in a dedicated renal impairment study","volume":"55","author":"J\u00f6nsson","year":"2015","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.chest.2019.05.025_bib16","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1365-2125.2010.03753.x","article-title":"Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor xa inhibitor","volume":"70","author":"Kubitza","year":"2010","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.chest.2019.05.025_bib17","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/jcph.628","article-title":"Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis","volume":"56","author":"Wang","year":"2016","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.chest.2019.05.025_bib18","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1681\/ASN.2016090980","article-title":"Apixaban pharmacokinetics at steady state in hemodialysis patients","volume":"28","author":"Mavrakanas","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.chest.2019.05.025_bib19","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.2215\/CJN.01570213","article-title":"Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience","volume":"8","author":"Singh","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.chest.2019.05.025_bib20","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/bcp.12114","article-title":"Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects","volume":"76","author":"Upreti","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.chest.2019.05.025_bib21","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2013.07.104","article-title":"The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: The RE-LY trial (Randomized Evaluation of Long-Term Anticoagulation Therapy)","volume":"63","author":"Reilly","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.chest.2019.05.025_bib22","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/jth.13323","article-title":"Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH","volume":"14","author":"Martin","year":"2016","journal-title":"J\u00a0Thromb Haemost"},{"issue":"8","key":"10.1016\/j.chest.2019.05.025_bib23","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1161\/CIRCULATIONAHA.115.020950","article-title":"Comparison of dabigatran and warfarin in patients with atrial fibrillation and valvular heart disease: the RE-LY trial (randomized evaluation of long-term anticoagulant therapy)","volume":"134","author":"Ezekowitz","year":"2016","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.chest.2019.05.025_bib24","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1474-4422(12)70017-0","article-title":"Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial","volume":"11","author":"Diener","year":"2012","journal-title":"Lancet Neurol"},{"issue":"47","key":"10.1016\/j.chest.2019.05.025_bib25","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1093\/eurheartj\/ehu305","article-title":"Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial","volume":"35","author":"Breithardt","year":"2014","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.chest.2019.05.025_bib26","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.jacc.2016.12.031","article-title":"Valvular heart disease patients on edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial","volume":"69","author":"De Caterina","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.chest.2019.05.025_bib27","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.114.014807","article-title":"Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial","volume":"132","author":"Avezum","year":"2015","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.chest.2019.05.025_bib28","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jacc.2017.03.011","article-title":"2017 AHA\/ACC focused update of the 2014 AHA\/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"70","author":"Nishimura","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"27","key":"10.1016\/j.chest.2019.05.025_bib29","first-page":"2137","article-title":"Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: executive summary","volume":"38","author":"Heidbuchel","year":"2017","journal-title":"Eur Heart J"},{"issue":"19","key":"10.1016\/j.chest.2019.05.025_bib30","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/j.jacc.2016.08.010","article-title":"Transcatheter aortic valve thrombosis: incidence, predisposing factors, and clinical implications","volume":"68","author":"Hansson","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.chest.2019.05.025_bib31","first-page":"110","article-title":"2017 ESC\/EACTS guidelines for the management of valvular heart disease","volume":"71","author":"Baumgartner","year":"2018","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"3","key":"10.1016\/j.chest.2019.05.025_bib32","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.amjcard.2017.10.035","article-title":"Meta-analysis of the safety and efficacy of the oral anticoagulant agents (apixaban, rivaroxaban, dabigatran) in patients with acute coronary syndrome","volume":"121","author":"Khan","year":"2018","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.chest.2019.05.025_bib33","doi-asserted-by":"crossref","DOI":"10.1161\/STR.0000000000000158","article-title":"2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"49","author":"Powers","year":"2018","journal-title":"Stroke"},{"issue":"9","key":"10.1016\/j.chest.2019.05.025_bib34","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.04.012","article-title":"Safety of recanalization therapy in patients with acute ischemic stroke under anticoagulation: a systematic review and meta-analysis","volume":"27","author":"Liu","year":"2018","journal-title":"J\u00a0Stroke Cerebrovasc Dis"},{"issue":"suppl_1","key":"10.1016\/j.chest.2019.05.025_bib35","doi-asserted-by":"crossref","first-page":"A4","DOI":"10.1161\/str.49.suppl_1.4","article-title":"Abstract 4: Safety of intravenous thrombolysis among patients taking direct oral anticoagulants: A systematic review and meta-analysis","volume":"49","author":"Shahjouei","year":"2018","journal-title":"Stroke"},{"key":"10.1016\/j.chest.2019.05.025_bib36","unstructured":"National Institutes of Health Clinical Center. Addressing real-world anticoagulant management issues in stroke (ARAMIS). NCT02478177. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2015. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02478177. Updated May 23, 2019."},{"key":"10.1016\/j.chest.2019.05.025_bib37","unstructured":"National Institutes of Health Clinical Center. Novel oral anticoagulants in stroke patients (NOACISP). NCT02353585. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2015. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02353585. Updated February 28,\u00a02019."},{"key":"10.1016\/j.chest.2019.05.025_bib38","unstructured":"National Institutes of Health Clinical Center. Rivaroxaban acute stroke safety study (RASS). NCT02279940. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2014. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02279940. Updated April 6,\u00a02016."},{"key":"10.1016\/j.chest.2019.05.025_bib39","unstructured":"National Institutes of Health Clinical Center. Rivaroxaban versus warfarin in acute ischemic stroke with atrial fibrillation (TripleAXEL). NCT02042534. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2014. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02042534. Updated February 8,\u00a02017."},{"key":"10.1016\/j.chest.2019.05.025_bib40","unstructured":"National Institutes of Health Clinical Center. Apixaban for early prevention of recurrent embolic stroke and hemorrhagic transformation (AREST). NCT02283294. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2014. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02283294. Updated March 19,\u00a02019."},{"issue":"4","key":"10.1016\/j.chest.2019.05.025_bib41","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.thromres.2015.01.009","article-title":"New oral anticoagulants in the treatment of heparin-induced thrombocytopenia","volume":"135","author":"Sharifi","year":"2015","journal-title":"Thromb Res"},{"issue":"2","key":"10.1016\/j.chest.2019.05.025_bib42","first-page":"397","article-title":"Non-vitamin K antagonist oral anticoagulants for heparin-induced thrombocytopenia. A systematic review of 54 reported cases","volume":"116","author":"Shatzel","year":"2016","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1016\/j.chest.2019.05.025_bib43","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/jth.13330","article-title":"Rivaroxaban for treatment of suspected or confirmed heparin-induced thrombocytopenia study","volume":"14","author":"Linkins","year":"2016","journal-title":"J\u00a0Thromb Haemost"},{"issue":"4","key":"10.1016\/j.chest.2019.05.025_bib44","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/ejh.12921","article-title":"Direct acting oral anticoagulants for the treatment of suspected heparin-induced thrombocytopenia","volume":"99","author":"Davis","year":"2017","journal-title":"Eur J Haematol"},{"issue":"9","key":"10.1016\/j.chest.2019.05.025_bib45","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood-2017-04-778993","article-title":"Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review","volume":"130","author":"Warkentin","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.chest.2019.05.025_bib46","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1365-2141.2008.07300.x","article-title":"Rivaroxaban\u2014an oral, direct factor xa inhibitor\u2014has potential for the management of patients with heparin-induced thrombocytopenia","volume":"143","author":"Walenga","year":"2008","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.chest.2019.05.025_bib47","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s11239-014-1064-7","article-title":"Design of the rivaroxaban for heparin-induced thrombocytopenia study","volume":"38","author":"Linkins","year":"2014","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.chest.2019.05.025_bib48","unstructured":"National Institutes of Health Clinical Center. Efficacy and safety of apixaban in the treatment of heparin induced thrombocytopenia (HIT). NCT03594045. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2018. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03594045. Updated January 25,\u00a02019."},{"issue":"2","key":"10.1016\/j.chest.2019.05.025_bib49","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.chest.2019.05.025_bib50","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1177\/1076029618755311","article-title":"Apixaban or rivaroxaban versus warfarin for treatment of submassive pulmonary embolism after catheter-directed thrombolysis","volume":"24","author":"Groetzinger","year":"2018","journal-title":"Clin Appl Thromb Hemost"},{"issue":"3","key":"10.1016\/j.chest.2019.05.025_bib51","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ccm.2018.04.002","article-title":"Prevention of deep vein thrombosis and pulmonary embolism in high-risk medical patients","volume":"39","author":"McCullough","year":"2018","journal-title":"Clin Chest Med"},{"issue":"23","key":"10.1016\/j.chest.2019.05.025_bib52","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1110899","article-title":"Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients","volume":"365","author":"Goldhaber","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.chest.2019.05.025_bib53","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa1111096","article-title":"Rivaroxaban for thromboprophylaxis in acutely ill medical patients","volume":"368","author":"Cohen","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.chest.2019.05.025_bib54","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1056\/NEJMoa1601747","article-title":"Extended thromboprophylaxis with betrixaban in acutely ill medical patients","volume":"375","author":"Cohen","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.chest.2019.05.025_bib55","first-page":"25","article-title":"Direct oral anticoagulants for extended thromboprophylaxis in medically ill patients: meta-analysis and risk\/benefit assessment","volume":"9","author":"Al Yami","year":"2018","journal-title":"J\u00a0Blood Med"},{"issue":"5","key":"10.1016\/j.chest.2019.05.025_bib56","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1182\/blood-2016-10-747931","article-title":"Extended thromboprophylaxis with direct oral anticoagulants for medical patients: a systematic review and meta-analysis","volume":"129","author":"Tao","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.chest.2019.05.025_bib57","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11239-016-1461-1","article-title":"Extended-duration versus short-duration pharmacological thromboprophylaxis in acutely ill hospitalized medical patients: a systematic review and meta-analysis of randomized controlled trials","volume":"43","author":"Liew","year":"2017","journal-title":"J\u00a0Thromb Thrombolysis"},{"issue":"5","key":"10.1016\/j.chest.2019.05.025_bib58","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/jth.13670","article-title":"Thrombotic and bleeding outcomes following perioperative interruption of direct oral anticoagulants in patients with venous thromboembolic disease","volume":"15","author":"Shaw","year":"2017","journal-title":"J\u00a0Thromb Haemost"},{"issue":"2","key":"10.1016\/j.chest.2019.05.025_bib59","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/rth2.12084","article-title":"Direct oral anticoagulant use and risk of perioperative bleeding: evidence of absence or absence of evidence?","volume":"2","author":"Lijfering","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"issue":"6","key":"10.1016\/j.chest.2019.05.025_bib60","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.pcad.2018.03.002","article-title":"Peri-procedural management of oral anticoagulants in the DOAC era","volume":"60","author":"Barnes","year":"2018","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.chest.2019.05.025_bib61","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12959-017-0137-1","article-title":"Perioperative management of patients on direct oral anticoagulants","volume":"15","author":"Dubois","year":"2017","journal-title":"Thromb J"},{"issue":"5","key":"10.1016\/j.chest.2019.05.025_bib62","doi-asserted-by":"crossref","first-page":"536.e1","DOI":"10.1016\/j.jamcollsurg.2018.08.183","article-title":"American College of Surgeons' guidelines for the perioperative management of antithrombotic medication","volume":"227","author":"Hornor","year":"2018","journal-title":"J\u00a0Am Coll Surg"},{"issue":"44","key":"10.1016\/j.chest.2019.05.025_bib63","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1093\/eurheartj\/ehy413","article-title":"Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2)","volume":"39","author":"Birnie","year":"2018","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.chest.2019.05.025_bib64","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.recesp.2018.01.001","article-title":"Perioperative and periprocedural management of antithrombotic therapy: consensus document of SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH, SETH, SEMERGEN, SEMFYC, SEMG, SEMICYUC, SEMI, SEMES, SEPAR, SENEC, SEO, SEPA, SERVEI, SECOT and AEU","volume":"71","author":"Vivas","year":"2018","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"4","key":"10.1016\/j.chest.2019.05.025_bib65","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/ejh.13208","article-title":"The efficacy and safety of direct oral anticoagulants in patients with chronic renal insufficiency: a review of the literature","volume":"102","author":"Weber","year":"2019","journal-title":"Eur J Haematol"},{"issue":"17","key":"10.1016\/j.chest.2019.05.025_bib66","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1136\/heartjnl-2016-310581","article-title":"Perioperative management of anticoagulant and antiplatelet therapy","volume":"104","author":"Tafur","year":"2018","journal-title":"Heart"},{"issue":"2","key":"10.1016\/j.chest.2019.05.025_bib67","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/rth2.12076","article-title":"Perioperative interruption of direct oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis","volume":"2","author":"Shaw","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"issue":"3","key":"10.1016\/j.chest.2019.05.025_bib68","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1161\/CIRCULATIONAHA.115.015688","article-title":"Perioperative management of dabigatran: a prospective cohort study","volume":"132","author":"Schulman","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.chest.2019.05.025_bib69","unstructured":"ClinicalTrials.gov. NCT02228798."},{"issue":"12","key":"10.1016\/j.chest.2019.05.025_bib70","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1160\/TH17-08-0553","article-title":"The perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) study for patients on a direct oral anticoagulant who need an elective surgery or procedure: design and rationale","volume":"117","author":"Douketis","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.chest.2019.05.025_bib71","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ahj.2017.10.002","article-title":"Is there a role for pharmacokinetic\/pharmacodynamic-guided dosing for novel oral anticoagulants?","volume":"199","author":"Chan","year":"2018","journal-title":"Am Heart J"},{"issue":"11","key":"10.1016\/j.chest.2019.05.025_bib72","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jacc.2014.05.065","article-title":"Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants","volume":"64","author":"Cuker","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.chest.2019.05.025_bib73","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/jamacardio.2017.0364","article-title":"Laboratory monitoring of non-vitamin K antagonist oral anticoagulant use in patients with atrial fibrillation: a review","volume":"2","author":"Eikelboom","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"6","key":"10.1016\/j.chest.2019.05.025_bib74","first-page":"1263","article-title":"Clinical laboratory measurement of direct factor xa inhibitors: anti-xa assay is preferable to prothrombin time assay","volume":"104","author":"Barrett","year":"2010","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.chest.2019.05.025_bib75","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"Schulman","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"issue":"9591","key":"10.1016\/j.chest.2019.05.025_bib76","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","article-title":"Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial","volume":"370","author":"Eriksson","year":"2007","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.chest.2019.05.025_bib77","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/j.1538-7836.2007.02748.x","article-title":"Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial","volume":"5","author":"Eriksson","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"issue":"26","key":"10.1016\/j.chest.2019.05.025_bib78","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty","volume":"358","author":"Eriksson","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.chest.2019.05.025_bib79","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.thromres.2014.09.011","article-title":"Safety and efficacy of edoxaban, an oral factor xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial","volume":"134","author":"Fuji","year":"2014","journal-title":"Thromb Res"},{"key":"10.1016\/j.chest.2019.05.025_bib80","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12959-015-0057-x","article-title":"Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V","volume":"13","author":"Fuji","year":"2015","journal-title":"Thrombosis J"},{"issue":"9632","key":"10.1016\/j.chest.2019.05.025_bib81","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","article-title":"Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial","volume":"372","author":"Kakkar","year":"2008","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.chest.2019.05.025_bib82","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1056\/NEJMoa0810773","article-title":"Apixaban or enoxaparin for thromboprophylaxis after knee replacement","volume":"361","author":"Lassen","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.chest.2019.05.025_bib83","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa1006885","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after hip replacement","volume":"363","author":"Lassen","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"9717","key":"10.1016\/j.chest.2019.05.025_bib84","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(09)62125-5","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial","volume":"375","author":"Lassen","year":"2010","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.chest.2019.05.025_bib85","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty","volume":"358","author":"Lassen","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"9676","key":"10.1016\/j.chest.2019.05.025_bib86","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial","volume":"373","author":"Turpie","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.chest.2019.05.025_bib87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.arth.2008.01.132","article-title":"Oral thrombin inhibitor dabigatran etexilate vs\u00a0North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery","volume":"24","author":"Ginsberg","year":"2009","journal-title":"J\u00a0Arthroplasty"},{"issue":"10","key":"10.1016\/j.chest.2019.05.025_bib88","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.amjcard.2017.02.015","volume":"119","author":"Steinberg","year":"2017","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.chest.2019.05.025_bib89","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.chest.2017.02.009","article-title":"Direct oral anticoagulant- or warfarin-related major bleeding: characteristics, reversal strategies, and outcomes from a multicenter observational study","volume":"152","author":"Xu","year":"2017","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.chest.2019.05.025_bib90","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.2870","article-title":"Assessment of outcomes of treatment with oral anticoagulants in patients with atrial fibrillation and multiple chronic conditions: a comparative effectiveness analysis","volume":"1","author":"Mentias","year":"2018","journal-title":"JAMA Network Open"},{"issue":"26","key":"10.1016\/j.chest.2019.05.025_bib91","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.chest.2019.05.025_bib92","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.chest.2019.05.025_bib93","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","article-title":"Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation\u2014the J-ROCKET AF study","volume":"76","author":"Hori","year":"2012","journal-title":"Circ J"},{"issue":"1","key":"10.1016\/j.chest.2019.05.025_bib94","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.chest.2019.05.025_bib95","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"Buller","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.chest.2019.05.025_bib96","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMoa1805090","article-title":"Rivaroxaban for thromboprophylaxis after hospitalization for medical illness","volume":"379","author":"Spyropoulos","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.chest.2019.05.025_bib97","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.chest.2019.05.025_bib98","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.chest.2019.05.025_bib99","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/CIRCULATIONAHA.113.004450","article-title":"Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis","volume":"129","author":"Schulman","year":"2014","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.chest.2019.05.025_bib100","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"Extended use of dabigatran, warfarin, or placebo in venous thromboembolism","volume":"368","author":"Schulman","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.chest.2019.05.025_bib101","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.chest.2019.05.025_bib102","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.chest.2019.05.025_bib103","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.chest.2019.05.025_bib104","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.chest.2019.05.025_bib105","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"Buller","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.chest.2019.05.025_bib106","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.chest.2019.05.025_bib107","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMc1007378","article-title":"Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial","volume":"363","author":"Connolly","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.chest.2019.05.025_bib108","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1253\/circj.CJ-14-0942","article-title":"Short-term safety and plasma concentrations of edoxaban in Japanese patients with non-valvular atrial fibrillation and severe renal impairment","volume":"79","author":"Koretsune","year":"2015","journal-title":"Circ J"},{"issue":"1","key":"10.1016\/j.chest.2019.05.025_bib109","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2165\/00002018-200831010-00006","article-title":"Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation","volume":"31","author":"Kubitza","year":"2008","journal-title":"Drug Saf"},{"issue":"5","key":"10.1016\/j.chest.2019.05.025_bib110","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/jcph.447","article-title":"Randomized, blinded, placebo- and positive-controlled crossover study to determine the effect of multiple doses of apixaban on the QTc interval","volume":"55","author":"Frost","year":"2015","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.chest.2019.05.025_bib111","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1177\/0091270010381901","article-title":"A\u00a0thorough electrocardiogram study of edoxaban, a novel factor xa inhibitor","volume":"51","author":"Mendell","year":"2011","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.chest.2019.05.025_bib112","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","article-title":"Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report","volume":"154","author":"Lip","year":"2018","journal-title":"Chest"},{"issue":"22","key":"10.1016\/j.chest.2019.05.025_bib113","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1182\/bloodadvances.2018024893","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: Optimal management of anticoagulation therapy","volume":"2","author":"Witt","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.chest.2019.05.025_bib114","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jcrc.2018.08.031","article-title":"Tolerability and effectiveness of 4-factor prothrombin complex concentrate (4F-PCC) for warfarin and non-warfarin reversals","volume":"48","author":"Santibanez","year":"2018","journal-title":"J\u00a0Crit Care"},{"issue":"suppl 2","key":"10.1016\/j.chest.2019.05.025_bib115","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2516.2004.00935.x","article-title":"FEIBA safety profile in multiple modes of clinical and home-therapy application","volume":"10","author":"Luu","year":"2004","journal-title":"Haemophilia"},{"issue":"4","key":"10.1016\/j.chest.2019.05.025_bib116","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.thromres.2015.07.012","article-title":"The impact of a three-factor prothrombin complex concentrate on the anticoagulatory effects of the factor xa inhibitor edoxaban","volume":"136","author":"Brown","year":"2015","journal-title":"Thromb Res"},{"issue":"2","key":"10.1016\/j.chest.2019.05.025_bib117","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ajem.2018.05.023","article-title":"Safety and effectiveness of Factor Eight Inhibitor Bypassing Activity for direct oral anticoagulant-related hemorrhage reversal","volume":"37","author":"Engelbart","year":"2019","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.chest.2019.05.025_bib118","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.thromres.2017.02.010","article-title":"Reversal of dabigatran-associated major bleeding with activated prothrombin concentrate: a prospective cohort study","volume":"152","author":"Schulman","year":"2017","journal-title":"Thromb Res"},{"issue":"5","key":"10.1016\/j.chest.2019.05.025_bib119","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jemermed.2016.11.011","article-title":"Factor eight inhibitor bypassing agent (FEIBA) for reversal of target-specific oral anticoagulants in life-threatening intracranial bleeding","volume":"52","author":"Mao","year":"2017","journal-title":"J\u00a0Emerg Med"},{"issue":"1","key":"10.1016\/j.chest.2019.05.025_bib120","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12028-017-0383-x","article-title":"Safety and effectiveness of factor VIII inhibitor bypassing activity (FEIBA) and fresh frozen plasma in oral anticoagulant-associated intracranial hemorrhage: a retrospective analysis","volume":"27","author":"Yin","year":"2017","journal-title":"Neurocrit Care"},{"issue":"5","key":"10.1016\/j.chest.2019.05.025_bib121","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal\u2014full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.chest.2019.05.025_bib122","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","article-title":"Andexanet\u00a0alfa for acute major bleeding associated with factor xa inhibitors","volume":"375","author":"Connolly","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.chest.2019.05.025_bib123","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3109\/15563650.2015.1004580","article-title":"Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran","volume":"53","author":"Bouchard","year":"2015","journal-title":"Clin Toxicol (Phila)"},{"issue":"2","key":"10.1016\/j.chest.2019.05.025_bib124","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1160\/TH16-03-0224","article-title":"Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban","volume":"117","author":"Ansell","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.chest.2019.05.025_bib125","unstructured":"National Institutes of Health Clinical Center. Phase 2 study of apixaban reversal by ciraparantag as measured by WBCT. NCT03288454. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2017. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03288454. Updated November 2, 2018."}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369219312267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369219312267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T08:11:28Z","timestamp":1757923888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369219312267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":125,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0012369219312267"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2019.05.025","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Direct-Acting Oral Anticoagulants in Critically Ill Patients","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2019.05.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}